- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02020122
Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles
1. oktober 2017 opdateret af: d_yarnitsky, Rambam Health Care Campus
To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived morbidity.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
In the project proposed here our main aim is to shift pain modulation towards anti-nociception as a novel approach to pain prevention and treatment.
Our first hypothesis is that individual's modulation profile, when not anti-nociceptive, can be pharmacologically shifted into being anti-nociceptive.
We assert (the first hypothesis) that such shift can be optimized by coupling the drug's mode of action with the individual's pain modulation profile; based on limited available data, it is suggested that less efficient inhibitory pain modulation will be modified best by serotonin-norepinephrine reuptake inhibitors (SNRIs), whereas enhanced facilitatory modulation will be modified best by Ca++ channel ligands.
Pain modulation will be assessed by psychophysical tools, and will include dynamic tests of pain modulation.
The conditioned pain modulation (CPM) test protocol will be used for assessing pain inhibition, and the temporal summation (TS) test protocol will be used for assessment of pain facilitation.
Our second hypothesis is that SNRIs will be most efficacious in shifting individuals into being antinociceptive if these individuals had lower activation of the anterior brain pain network in the CPM test paradigm.
In turn, Ca++ channel ligands will be most efficacious for individuals showing enhanced activation of the posterior pain network sites in response to the TS test protocol.
Our third hypothesis is that an anti-nociceptive pain modulation profile protects individuals from acquiring pain.
The model we chose for this study is surgery for coronary artery bypass grafting (CABG).
Individuals scheduled for surgery, who are pain free, will be assigned to 3 arms - (1) duloxetine (DUL) (SNRI), (2) pregabalin (PGB) (Ca++ channel ligand) and (3) placebo.
Drugs will be taken for 48 hours prior to surgery in a double-blind non cross-over parallel design.
Pain modulation will be assessed before treatment, 2-4 hours prior to surgery and at its end, 6 weeks before surgery.
Post operative acute and chronic pain will be assessed up to 2 month after surgery.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
5
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Haifa, Israel
- Rambam Health Care Campus
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Otherwise healthy, age 18-75.
Exclusion Criteria:
- Regular use of analgesia for any purpose, including SNRIs, gabapentins, COX inhibitors.
- Presence of diagnosed chronic pain disorders, psychiatric disorders, cognitive and /or neurological deficit.
- Inability to give informed consent, communicate and understand the purpose and instructions of this study.
- Pregnant or nursing women.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Duloxetine
DUL 60mg x once a day x 2 days.
This arm will also take 2 non-active placebo x once a day x 2 days
|
duloxetine 60mg
non active placebo
|
|
Aktiv komparator: Pregabalin
PGB 150mg x twice a day x 2 days
|
pregabalin 150mg
|
|
Placebo komparator: Placebo
Non active placebo x twice a day x 2 days
|
non active placebo
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The changes in pain response after administration of duloxetine and pregabalin
Tidsramme: 3 years
|
The changes in the excitatory and inhibitory pain modulation responses (assessed by temporal summation and conditioned pain modulation) will be examined before and after the administration of duloxetine and pregabalin in the set of pre and post coronary artery bypass grafting surgery.
|
3 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. januar 2014
Primær færdiggørelse (Faktiske)
1. januar 2015
Studieafslutning (Faktiske)
1. januar 2015
Datoer for studieregistrering
Først indsendt
18. december 2013
Først indsendt, der opfyldte QC-kriterier
18. december 2013
Først opslået (Skøn)
24. december 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
4. oktober 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
1. oktober 2017
Sidst verificeret
1. oktober 2017
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Depressive midler til centralnervesystemet
- Agenter fra det perifere nervesystem
- Analgetika
- Sensoriske systemagenter
- Beroligende midler
- Psykotropiske stoffer
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Antidepressive midler
- Dopaminmidler
- Anti-angst midler
- Antikonvulsiva
- Serotonin- og Noradrenalin-genoptagelseshæmmere
- Calciumregulerende hormoner og midler
- Calciumkanalblokkere
- Duloxetinhydrochlorid
- Pregabalin
Andre undersøgelses-id-numre
- 0472-13-RMB.CTIL
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Smerte
-
Istanbul University - CerrahpasaRekrutteringPatellofemoral Pain, PfpTyrkiet (Türkiye)
-
Pamukkale UniversityIkke rekrutterer endnuPatellofemoral Pain, PfpTyrkiet (Türkiye)
-
Beijing Sport UniversityAfsluttetPatellofemoral Pain, PfpKina
-
Beijing Sport UniversityIkke rekrutterer endnuPatellofemoral Pain, Pfp
-
Beijing Sport UniversityIkke rekrutterer endnu
-
Sahmyook UniversityAfsluttetMyofascial Pain Syndrome (MPS)Sydkorea
-
Camilo Jose Cela UniversityAfsluttetMyofascial Pain Syndrome (MPS)Spanien
-
Izmir Tinaztepe UniversityEge UniversityIkke rekrutterer endnuRygliggende stilling | FLACC Skala | Behavioral Pain Scale
-
University of California, DavisNational Institutes of Health (NIH); National Center for Complementary...Ikke rekrutterer endnuKronisk lænderygsmerter (cLBP) | Myofascial Pain Syndrome (MPS)Forenede Stater
-
University of North Carolina, Chapel HillCanadian Institutes of Health Research (CIHR)AfsluttetPatellofemoralt smertesyndrom | Patellofemoral smerte (PFPS) | Patellofemoral smerte | Patellofemoral Pain, PfpForenede Stater
Kliniske forsøg med Duloxetine
-
Chattogram International Dental CollegeRekrutteringPost endodontisk smerte | Mekanisk detektionsterskel | Mekanisk Smertetærskel | Mekanisk SmertefølsomhedBangladesh
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Afsluttet
-
Boehringer IngelheimAfsluttetDiabetiske neuropatier | Depressiv lidelse, majorTyskland
-
University of MinnesotaHoffmann-La Roche; Minnesota Medical FoundationAfsluttetInfektiøs mononukleoseForenede Stater
-
University of PennsylvaniaIkke rekrutterer endnuInflammatoriske tarmsygdomme
-
Kafrelsheikh UniversityAfsluttetLeverskrumpe med diabetesEgypten
-
London Health Sciences Centre Research Institute...Afsluttet
-
Nearmedic Plus LLCAfsluttetHerpes simplex | Herpes Genitalis | Herpes | Herpes oral | Herpes simplex 2Den Russiske Føderation
-
Tasly Pharmaceutical Group Co., LtdAfsluttet
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RekrutteringMajor Depressive Disorder (MDD)Kina